---
title: "Tiziana Life Sciences Stock Jumps As Positive Preclinical Fuels Momentum"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281407400.md"
description: "Tiziana Life Sciences shares rose 7.26% to $1.25 following positive preclinical data on intranasal foralumab, which shows potential cognitive benefits and reduced neuroinflammation. The company is advancing clinical trials for conditions like Multiple Sclerosis and Alzheimer’s. However, technical indicators reveal mixed momentum, with the stock trading below its 20-day and 50-day moving averages, and an RSI of 37.33 indicating neutral territory. Key resistance is at $1.50 and support at $1.00."
datetime: "2026-04-01T17:10:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281407400.md)
  - [en](https://longbridge.com/en/news/281407400.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281407400.md)
---

# Tiziana Life Sciences Stock Jumps As Positive Preclinical Fuels Momentum

**Tiziana Life Sciences Ltd.** (NASDAQ:TLSA) shares are up on Wednesday following the announcement of positive preclinical data regarding its lead candidate, intranasal foralumab.

## Data Points To Cognitive Benefits And Reduced Neuroinflammation

The recent data highlight nasal anti-CD3’s potential in reversing cognitive decline associated with aging, which is a significant concern in neurodegenerative diseases.

Tiziana’s chairman, **Howard Weiner**, noted that these results reinforce the mechanism of action of intranasal foralumab, which stimulates regulatory T cells to reduce neuroinflammation.

Further emphasizing the importance of this research, CEO Ivor Elrifi stated that the findings support ongoing clinical programs for foralumab in conditions like Non-Active Secondary Progressive Multiple Sclerosis and Alzheimer’s disease.

The company is advancing its clinical trials while expanding its preclinical research into additional areas, including aging-related cognitive impairment.

## Technical Indicators Show Mixed Momentum

Currently, Tiziana is trading 3.8% below its 20-day simple moving average (SMA) and 10.7% below its 50-day SMA, indicating some short-term weakness.

Over the past 12 months, shares have increased by 21.70%, and they are positioned closer to their 52-week lows than highs, suggesting a cautious outlook.

The RSI is at 37.33, which is considered neutral territory, while the MACD shows a value of -0.0465, below its signal line at -0.0404, indicating bearish pressure on the stock.

The combination of neutral RSI and bearish MACD suggests mixed momentum, indicating that while the stock is not oversold, it is also not showing strong bullish signals.

-   **Key Resistance**: $1.50
-   **Key Support**: $1.00

**TLSA Stock Price Activity:** Tiziana Life Sciences shares were up 7.26% at $1.25 at the time of publication on Wednesday, according to Benzinga Pro data.

_Image via Shutterstock_

### Related Stocks

- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [TLSA.US](https://longbridge.com/en/quote/TLSA.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)

## Related News & Research

- [Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis](https://longbridge.com/en/news/286899753.md)
- [Biogen Conference: Lupus, Kidney Programs Take Center Stage in Immunology Push](https://longbridge.com/en/news/286623100.md)
- [Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data](https://longbridge.com/en/news/286652611.md)
- [Zydus buys US specialty drugmaker Assertio in Rs 1,600 crore all-cash deal](https://longbridge.com/en/news/286352725.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)